NASDAQ:KRON Kronos Bio (KRON) Stock Price, News & Analysis $0.95 +0.05 (+5.56%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Kronos Bio Stock (NASDAQ:KRON) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Kronos Bio alerts:Sign Up Key Stats Today's Range$0.92▼$0.9650-Day Range$0.90▼$1.0552-Week Range$0.69▼$1.60Volume31,270 shsAverage Volume279,856 shsMarket Capitalization$57.08 millionP/E RatioN/ADividend YieldN/APrice Target$4.13Consensus RatingBuy Company OverviewKronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Kronos Bio Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks58th Percentile Overall ScoreKRON MarketRank™: Kronos Bio scored higher than 58% of companies evaluated by MarketBeat, and ranked 398th out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingKronos Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKronos Bio has only been the subject of 2 research reports in the past 90 days.Read more about Kronos Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kronos Bio are expected to decrease in the coming year, from ($1.33) to ($1.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kronos Bio is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kronos Bio is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKronos Bio has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Kronos Bio's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.81% of the float of Kronos Bio has been sold short.Short Interest Ratio / Days to CoverKronos Bio has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Kronos Bio has recently decreased by 4.57%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKronos Bio does not currently pay a dividend.Dividend GrowthKronos Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.81% of the float of Kronos Bio has been sold short.Short Interest Ratio / Days to CoverKronos Bio has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Kronos Bio has recently decreased by 4.57%, indicating that investor sentiment is improving. News and Social Media1.1 / 5News Sentiment-0.08 News SentimentKronos Bio has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Kronos Bio this week, compared to 1 article on an average week. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kronos Bio insiders have not sold or bought any company stock.Percentage Held by Insiders23.40% of the stock of Kronos Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.09% of the stock of Kronos Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kronos Bio's insider trading history. Receive KRON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kronos Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address KRON Stock News HeadlinesKronos Bio announces preclinical data from p300 KAT inhibitor programOctober 24 at 1:15 AM | markets.businessinsider.comKronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven TumorsOctober 23 at 8:55 AM | globenewswire.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)Piper Sandler Remains a Buy on Kronos Bio (KRON)October 9, 2024 | markets.businessinsider.comKronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven TumorsOctober 9, 2024 | globenewswire.comKronos Bio (NASDAQ:KRON) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.comKronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s DiseaseOctober 8, 2024 | markets.businessinsider.comKronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's DiseaseOctober 7, 2024 | globenewswire.comSee More Headlines KRON Stock Analysis - Frequently Asked Questions How have KRON shares performed this year? Kronos Bio's stock was trading at $1.25 on January 1st, 2024. Since then, KRON shares have decreased by 24.0% and is now trading at $0.9499. View the best growth stocks for 2024 here. How were Kronos Bio's earnings last quarter? Kronos Bio, Inc. (NASDAQ:KRON) issued its quarterly earnings data on Thursday, August, 8th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.05. The company had revenue of $2.69 million for the quarter, compared to analysts' expectations of $1.75 million. Kronos Bio had a negative net margin of 1,222.83% and a negative trailing twelve-month return on equity of 68.82%. When did Kronos Bio IPO? Kronos Bio (KRON) raised $175 million in an initial public offering (IPO) on Friday, October 9th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO. How do I buy shares of Kronos Bio? Shares of KRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Kronos Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kronos Bio investors own include Bank of America (BAC), AT&T (T), Taseko Mines (TGB), Energy Transfer (ET), ARMOUR Residential REIT (ARR), Prospect Capital (PSEC) and New Gold (NGD). Company Calendar Last Earnings8/08/2024Today10/23/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KRON CUSIPN/A CIK1741830 Webkronosbio.com Phone650-781-5200FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$4.13 High Stock Price Target$6.00 Low Stock Price Target$2.25 Potential Upside/Downside+334.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,670,000.00 Net Margins-1,222.83% Pretax Margin-1,222.83% Return on Equity-68.82% Return on Assets-51.52% Debt Debt-to-Equity RatioN/A Current Ratio8.49 Quick Ratio8.49 Sales & Book Value Annual Sales$8.41 million Price / Sales6.79 Cash FlowN/A Price / Cash FlowN/A Book Value$2.73 per share Price / Book0.35Miscellaneous Outstanding Shares60,094,000Free Float45,583,000Market Cap$57.08 million OptionableOptionable Beta1.87 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (NASDAQ:KRON) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kronos Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kronos Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.